BILB 1941

Drug Profile

BILB 1941

Alternative Names: BILB 1941 ZW; BILB1941; BILN-1941

Latest Information Update: 16 Oct 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antivirals
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Oct 2014 Discontinued - Phase-I for Hepatitis C (In volunteers) in Germany (PO, tablet)
  • 01 Oct 2014 Discontinued - Phase-II for Hepatitis C in France, Germany and Spain (PO, solution)
  • 01 Apr 2006 Boehringer Ingelheim completes a phase II trial in Hepatitis C in France, Germany and Spain (NCT02254707)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top